ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

452

Enrollment

INDUSTRY

Sponsor class

Conditions

Anaplastic Large-Cell Lymphoma
Non-Hodgkin Lymphoma
T-Cell Lymphoma

Interventions

DRUG: brentuximab vedotin
DRUG: doxorubicin
DRUG: prednisone
DRUG: vincristine
DRUG: cyclophosphamide

Sponsor

Seagen Inc.

Collaborators

[object Object]